Group 1 - The core viewpoint of the news is that Sihuan Pharmaceutical has achieved a significant breakthrough in the medical aesthetics field with the approval of its self-developed injectable polycaprolactone microsphere facial filler, known as "girl needle" [1][2] - The "girl needle" is a regenerative injectable material that provides immediate filling effects and long-lasting results, with a single treatment lasting over one year [1][2] - The approval of the "girl needle" fills a gap in the company's portfolio of Class III medical devices and positions it among the top three products in the domestic market [2][3] Group 2 - The Chinese market for injectable regenerative materials is projected to grow from approximately 3 billion RMB in 2023 to about 7.2 billion RMB by 2025, with the market share increasing from 11% to 16% [2] - The "girl needle" series has seen over 50% year-on-year sales growth in 2023, indicating strong market demand and positive consumer response [2] - Sihuan Pharmaceutical has a pipeline of additional regenerative materials, including polylactic acid fillers and other innovative products, positioning the company to lead in the rapidly growing regenerative materials market [3]